Vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck — who led the earlier study — will head the new trial. ・Separately, the company also announced that it has initiated a voluntary recall in ...

InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug ...

Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% - - FDA approval anticipated with U.S. market ...

InspireMD (NSPR) is scheduled to report earnings on March 5, 2025. The last reported earnings were for reported on November 12, 2024 for Q3.

InspireMD Inc. Annual stock financials by MarketWatch. View the latest NSPR financial statements, income statements and financial ratios.

The average one-year price target for InspireMD (NASDAQ:NSPR) has been revised to 4.95 / share. This is an increase of 11.49% from the prior estimate of 4.44 dated October 31, 2023. The price target ...

The average one-year price target for InspireMD (NasdaqCM:NSPR) has been revised to $5.10 / share. This is an increase of 25.00% from the prior estimate of $4.08 dated February 1, 2026. The price ...